Diversified Trust Co Has $1.61 Million Stock Position in Edwards Lifesciences Corporation $EW

Key Points

• Diversified Trust Co cut its stake in Edwards Lifesciences by 45.7% in the first quarter, leaving it with 20,057 shares valued at about $1.61 million.
• Several institutional investors remain heavily invested in the company, and institutions overall own 79.46% of Edwards Lifesciences’ stock. Meanwhile, insiders have been selling shares, including recent sales by the CFO and a vice president.
• Edwards Lifesciences reported strong quarterly results, beating EPS and revenue estimates, while analysts currently rate the stock a Moderate Buy with a consensus price target of $95.96.

Diversified Trust Co lowered its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 45.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 20,057 shares of the medical research company's stock after selling 16,910 shares during the period. Diversified Trust Co's holdings in Edwards Lifesciences were worth $1,606,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. State Street Corp raised its position in shares of Edwards Lifesciences by 1.5% during the fourth quarter. State Street Corp now owns 25,991,524 shares of the medical research company's stock worth $2,215,777,000 after purchasing an additional 371,892 shares during the period. Wellington Management Group LLP grew its position in Edwards Lifesciences by 4.8% in the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company's stock valued at $1,857,934,000 after purchasing an additional 989,533 shares during the period. Norges Bank acquired a new stake in Edwards Lifesciences in the 4th quarter valued at $803,686,000. Morgan Stanley increased its stake in Edwards Lifesciences by 12.4% during the 4th quarter. Morgan Stanley now owns 7,314,292 shares of the medical research company's stock valued at $623,544,000 after purchasing an additional 804,942 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in Edwards Lifesciences by 66.1% during the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company's stock valued at $505,160,000 after purchasing an additional 2,359,128 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Activity

In other news, CFO Scott B. Ullem sold 13,000 shares of the company's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares of the company's stock, valued at $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company's stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 81,038 shares of company stock worth $6,683,255. Corporate insiders own 0.31% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a "hold" rating in a research note on Friday, April 24th. Mizuho set a $95.00 target price on shares of Edwards Lifesciences and gave the stock an "outperform" rating in a research report on Monday, April 13th. Royal Bank Of Canada restated an "outperform" rating and issued a $100.00 target price on shares of Edwards Lifesciences in a report on Tuesday, June 16th. Truist Financial set a $90.00 price target on shares of Edwards Lifesciences and gave the company a "hold" rating in a research report on Friday, April 24th. Finally, Robert W. Baird lifted their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the company a "neutral" rating in a research note on Friday, April 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $95.96.

Edwards Lifesciences Stock Performance

NYSE EW opened at $85.72 on Tuesday. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $89.60. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The firm has a market cap of $49.36 billion, a price-to-earnings ratio of 45.59, a PEG ratio of 2.19 and a beta of 0.87. The company has a fifty day moving average price of $83.52 and a 200-day moving average price of $83.13.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same period last year, the firm earned $0.64 earnings per share. The firm's revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.